This article was originally published by Healio Once-weekly selinexor, bortezomib and dexamethasone improved outcomes compared with twice-weekly bortezomib and dexamethasone for pretreated multiple myeloma, according to results presented during the ASCO20 Virtual Scientific Program. Findings from the randomized phase 3 BOSTON study showed prolonged PFS and a higher objective response rate in the experimental group....
Continue Reading
This article was originally published by AJMC There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to meaningful advances in the therapy of multiple myeloma. However, investigators will first need to clear a number of key hurdles. Chimeric antigen receptor (CAR) gene-modified T-cell therapy appears to have considerable promise for patients with multiple...
Continue Reading
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple myeloma. Although stem cell mobilization is successful in the majority of patients with multiple myeloma, the use of granulocyte colony-stimulating factor (G-CSF) used alone is associated with up to a 10% failure rate, Kumar explains....
Continue Reading
The impact of age, ethnicity and socio-economic deprivation in the era of novel anti-myeloma agents is unclear. Using linked national data from New Zealand, we evaluated the incidence, prevalence and overall survival (OS) of individuals who were diagnosed with myeloma between 2004 and 2016. The crude incidence rate increased from 5.42 to 8.47/100 000 and...
Continue Reading
1 5 6 7

Floor 7, 90 The Terrace
Wellington Central
New Zealand